Related Experiment Videos

Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease

Eric Villeneuve1, Rubina Sunderji

  • 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

The Annals of Pharmacotherapy
|February 25, 2005
PubMed

Insights

Limited data exists on glycoprotein IIb/IIIa inhibitors (GPIs) for percutaneous coronary intervention (PCI) in end-stage renal disease (ESRD) patients. More research is needed to assess the benefits and risks of GPI therapy in this population.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Glycoprotein IIb/IIIa inhibitors (GPIs) are established adjunctive therapies for percutaneous coronary intervention (PCI).
  • Limited information is available regarding the efficacy and safety of GPIs in patients with end-stage renal disease (ESRD).

Purpose of the Study:

  • To evaluate the effectiveness and safety of GPIs as adjunctive therapy during PCI in patients with ESRD.

Main Methods:

  • Searched MEDLINE, EMBASE, and International Pharmaceutical Abstracts (1966-2004).
  • Conducted a manual bibliographic search.
  • Reviewed three reports on abciximab use in ESRD patients.

Main Results:

  • Found only three reports detailing abciximab use in ESRD patients undergoing PCI.
  • Limited data from registries and chart reviews make definitive conclusions difficult.
  • Individual case assessment is necessary for deciding on abciximab use in ESRD.

Conclusions:

  • Further studies are required to determine the benefit-risk profile of GPI therapy in ESRD patients.
  • The utility of GPIs in ESRD patients undergoing PCI remains uncertain.
Abstract

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...